Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

2.7K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.7K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.9K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.9K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.2K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.2K
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.3K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.3K
Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.5K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.5K
Tissue Transplantation01:24

Tissue Transplantation

1.3K
Tissue transplantation is a significant medical procedure involving the transfer of cells, tissues, or organs from a donor to a recipient, with the primary aim of restoring lost functions. This procedure is crucial in treating a broad spectrum of diseases, including kidney diseases, liver failure, heart disease, and certain types of cancers.
The Biology of Tissue Transplantation
The biology of tissue transplantation hinges on the Major Histocompatibility Complex (MHC) molecules. These molecules...
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility and safety of rapid glofitamab ramp-up.

Leukemia·2026
Same author

Non-myeloablative versus reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia patients aged ≥65: a study from the ALWP of EBMT.

Bone marrow transplantation·2026
Same author

The impact of IPI risk factors on CAR T-cell therapy or allogeneic stem cell transplantation for treatment of relapsed or refractory large B-cell lymphoma (LBCL).

Bone marrow transplantation·2026
Same author

Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.

Leukemia·2026
Same author

High-risk single-refractory and double-refractory chronic lymphocytic leukemia: feasibility and impact of alloHCT.

Blood advances·2026
Same author

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT.

Bone marrow transplantation·2026
Same journal

Evaluation of a novel eHealth-facilitated, post HCT-integrated care model on implementation and rehospitalization: results from the Swiss SMILe hybrid-RCT.

Bone marrow transplantation·2026
Same journal

Impact of doublet post-transplant maintenance on outcomes in multiple myeloma: A propensity score matching analysis.

Bone marrow transplantation·2026
Same journal

A multimodal sexual health intervention among hematopoietic stem cell transplant recipients: mediating effects on quality of life and mood.

Bone marrow transplantation·2026
Same journal

Excellent clinical and patient-reported outcomes following matched sibling donor BMT for sickle cell disease.

Bone marrow transplantation·2026
Same journal

The risk of anxiety and depression in Swedish potential stem cell donors-need for increased psychological evaluation and support?

Bone marrow transplantation·2026
Same journal

False-positive HIV-1 RNA detection following obecabtagene autoleucel.

Bone marrow transplantation·2026
See all related articles

Related Experiment Video

Updated: Apr 16, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

2.1K

Blood cell-derived transplants at 40.

Anthony D Ho1, Peter Dreger2, Christopher Juttner3

  • 1Department of Medicine V, University of Heidelberg, Heidelberg, Germany. anthony_dick.ho@urz.uni-heidelberg.de.

Bone Marrow Transplantation
|April 14, 2026
PubMed
Summary
This summary is machine-generated.

Forty years ago, the first successful transplant used blood-derived stem cells after chemotherapy for Burkitt lymphoma. This method now dominates transplants, offering faster recovery and fewer complications than bone marrow grafts.

More Related Videos

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

16.1K
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 25, 2007

14.1K

Related Experiment Videos

Last Updated: Apr 16, 2026

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis
03:40

Author Spotlight: Exploring the Lifespan Dynamics of Healthy Human Hematopoiesis

Published on: December 8, 2023

2.1K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

16.1K
Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells
22:06

Derivation of Hematopoietic Stem Cells from Murine Embryonic Stem Cells

Published on: February 25, 2007

14.1K

Area of Science:

  • Hematology
  • Transplant Immunology
  • Oncology

Background:

  • The 40th anniversary of the first publication on rapid hematopoietic recovery after high-dose chemotherapy and autologous blood stem cell infusion is noted.
  • This landmark event involved a patient with advanced Burkitt lymphoma who achieved remission and remains alive.

Purpose of the Study:

  • To highlight the evolution and impact of blood-derived progenitor cell transplants over 40 years.
  • To compare outcomes and complications of blood-derived versus bone marrow-derived grafts.
  • To discuss the role of blood-derived grafts in advancing cell-based therapies.

Main Methods:

  • Review of historical data and clinical outcomes related to hematopoietic stem cell transplantation.
  • Comparison of short-term complications and long-term outcomes between blood-derived and bone marrow-derived grafts.
  • Analysis of the impact of graft source on graft-versus-host disease (GvHD) in allotransplants.

Main Results:

  • Blood-derived progenitor cell transplants have become the standard for autotransplants and allotransplants.
  • These grafts facilitate rapid hematopoietic recovery, leading to fewer short-term complications and improved outcomes in many cases.
  • While generally beneficial, blood-derived grafts may be associated with increased graft-versus-host disease (GvHD) in allotransplant settings.

Conclusions:

  • The shift to blood-derived grafts has significantly improved transplant efficiency and patient outcomes.
  • Blood-derived grafts have reduced healthcare costs and enabled innovations in cell-based immunotherapy, including gene and chimeric antigen receptor (CAR)-T-cell therapies.
  • Further research into managing GvHD in allotransplants with blood-derived grafts is warranted.